{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:09:16Z","timestamp":1794920956402,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart failure with preserved ejection fraction (HFpEF). The mechanism behind these effects is not fully understood, and it remains unclear if they could be further enhanced by additional SGLT-1 inhibition. We investigated the effects of chronic treatment with the dual SGLT-1&amp;2 inhibitor sotagliflozin on left atrial (LA) remodeling and cellular arrhythmogenesis (i.e. atrial cardiomyopathy) in a metabolic syndrome-related rat model of HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      17\u00a0week-old ZSF-1 obese rats, a metabolic syndrome-related model of HFpEF, and wild type rats (Wistar Kyoto), were fed 30\u00a0mg\/kg\/d sotagliflozin for 6\u00a0weeks. At 23\u00a0weeks, LA were imaged in-vivo by echocardiography. In-vitro, Ca\n                      <jats:sup>2+<\/jats:sup>\n                      transients (CaT; electrically stimulated, caffeine-induced) and spontaneous Ca\n                      <jats:sup>2+<\/jats:sup>\n                      release were recorded by ratiometric microscopy using Ca\n                      <jats:sup>2+<\/jats:sup>\n                      -sensitive fluorescent dyes (Fura-2) during various experimental protocols. Mitochondrial structure (dye: Mitotracker), Ca\n                      <jats:sup>2+<\/jats:sup>\n                      buffer capacity (dye: Rhod-2), mitochondrial depolarization (dye: TMRE) and production of reactive oxygen species (dye: H2DCF) were visualized by confocal microscopy. Statistical analysis was performed with 2-way analysis of variance followed by post-hoc Bonferroni and student\u2019s t-test, as applicable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sotagliflozin ameliorated LA enlargement in HFpEF in-vivo. In-vitro\n                      <jats:italic>,<\/jats:italic>\n                      LA cardiomyocytes in HFpEF showed an increased incidence and amplitude of arrhythmic spontaneous Ca\n                      <jats:sup>2+<\/jats:sup>\n                      release events (SCaEs). Sotagliflozin significantly reduced the magnitude of SCaEs, while their frequency was unaffected. Sotagliflozin lowered diastolic [Ca\n                      <jats:sup>2+<\/jats:sup>\n                      ] of CaT at baseline and in response to glucose influx, possibly related to a ~\u200950% increase of sodium sodium\u2013calcium exchanger (NCX) forward-mode activity. Sotagliflozin prevented mitochondrial swelling and enhanced mitochondrial Ca\n                      <jats:sup>2+<\/jats:sup>\n                      buffer capacity in HFpEF. Sotagliflozin improved mitochondrial fission and reactive oxygen species (ROS) production during glucose starvation and averted Ca\n                      <jats:sup>2+<\/jats:sup>\n                      accumulation upon glycolytic inhibition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The SGLT-1&amp;2 inhibitor sotagliflozin ameliorated LA remodeling in metabolic HFpEF. It also improved distinct features of Ca\n                      <jats:sup>2+<\/jats:sup>\n                      -mediated cellular arrhythmogenesis in-vitro (i.e. magnitude of SCaEs, mitochondrial Ca\n                      <jats:sup>2+<\/jats:sup>\n                      buffer capacity, diastolic Ca\n                      <jats:sup>2+<\/jats:sup>\n                      accumulation, NCX activity). The safety and efficacy of combined SGLT-1&amp;2 inhibition for the treatment and\/or prevention of atrial cardiomyopathy associated arrhythmias should be further evaluated in clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-020-01208-z","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T13:04:01Z","timestamp":1610024641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF"],"prefix":"10.1186","volume":"20","author":[{"given":"David","family":"Bode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Wakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Primessnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Beindorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Dahmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Ruetten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Oeing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Alogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Messroghli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkert M.","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank R.","family":"Heinzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0194-4615","authenticated-orcid":false,"given":"Felix","family":"Hohendanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"2","key":"1208_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ehf2.12260","volume":"5","author":"F Hohendanner","year":"2018","unstructured":"Hohendanner F, Messroghli D, Bode D, Blaschke F, Parwani A, Boldt LH, Heinzel FR. Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction. ESC Heart Fail. 2018;5(2):211\u201321.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"1208_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10741-017-9657-9","volume":"23","author":"F Hohendanner","year":"2018","unstructured":"Hohendanner F, Heinzel FR, Blaschke F, Pieske BM, Haverkamp W, Boldt HL, Parwani AS. Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure. Heart Fail Rev. 2018;23(1):27\u201336.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"1208_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.joa.2016.05.002","volume":"32","author":"A Goette","year":"2016","unstructured":"Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D\u2019Avila A, Dobrev D, et al. EHRA\/HRS\/APHRS\/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. J Arrhythm. 2016;32(4):247\u201378.","journal-title":"J Arrhythm"},{"issue":"5","key":"1208_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417\u201327.","journal-title":"N Engl J Med"},{"issue":"15","key":"1208_CR5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141(15):1227\u201334.","journal-title":"Circulation"},{"issue":"21","key":"1208_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"10","key":"1208_CR7","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db13-0604","volume":"62","author":"MA Abdul-Ghani","year":"2013","unstructured":"Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans. Diabetes. 2013;62(10):3324\u20138.","journal-title":"Diabetes"},{"issue":"7","key":"1208_CR8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/bcp.14248","volume":"86","author":"RA de Boer","year":"2020","unstructured":"de Boer RA, Nunez J, Kozlovski P, Wang Y, Proot P, Keefe D. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. Br J Clin Pharmacol. 2020;86(7):1346\u201356.","journal-title":"Br J Clin Pharmacol"},{"key":"1208_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/DMSO.S233538","volume":"13","author":"BM Bonora","year":"2020","unstructured":"Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diabetes Metab Syndr Obes. 2020;13:161\u201374.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"1208_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.2012.58","volume":"92","author":"B Zambrowicz","year":"2012","unstructured":"Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, et al. LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92(2):158\u201369.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1208_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","volume":"19","author":"J Sabatino","year":"2020","unstructured":"Sabatino J, De Rosa S, Tamme L, Iaconetti C, Sorrentino S, Polimeni A, Mignogna C, Amorosi A, Spaccarotella C, Yasuda M, et al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020;19(1):66.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1208_CR12","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1210\/clinem\/dgz258","volume":"105","author":"DR Powell","year":"2020","unstructured":"Powell DR, Zambrowicz B, Morrow L, Beysen C, Hompesch M, Turner S, Hellerstein M, Banks P, Strumph P, Lapuerta P. Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. J Clin Endocrinol Metab. 2020;105(4):e1235\u201349.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1208_CR13","doi-asserted-by":"publisher","first-page":"e0130605","DOI":"10.1371\/journal.pone.0130605","volume":"10","author":"Y Kashiwagi","year":"2015","unstructured":"Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka TD, Ito K, Harada T, Takahashi H, Ikegami M, Anzawa R, Yoshimura M. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS ONE. 2015;10(6):e0130605.","journal-title":"PLoS ONE"},{"issue":"9","key":"1208_CR14","doi-asserted-by":"publisher","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","volume":"4","author":"R Lambert","year":"2015","unstructured":"Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular Na+ concentration ([Na+]i) Is Elevated In Diabetic Hearts Due To Enhanced Na+-glucose cotransport. J Am Heart Assoc. 2015;4(9):e002183.","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"1208_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","volume":"72","author":"SB Seidelmann","year":"2018","unstructured":"Seidelmann SB, Feofanova E, Yu B, Franceschini N, Claggett B, Kuokkanen M, Puolijoki H, Ebeling T, Perola M, Salomaa V, et al. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. J Am Coll Cardiol. 2018;72(15):1763\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1208_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvp190","volume":"84","author":"SK Banerjee","year":"2009","unstructured":"Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84(1):111\u20138.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1208_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/JOE-11-0122","volume":"210","author":"VP Bilan","year":"2011","unstructured":"Bilan VP, Salah EM, Bastacky S, Jones HB, Mayers RM, Zinker B, Poucher SM, Tofovic SP. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol. 2011;210(3):293\u2013308.","journal-title":"J Endocrinol"},{"issue":"6","key":"1208_CR18","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","volume":"6","author":"N Hamdani","year":"2013","unstructured":"Hamdani N, Franssen C, Lourenco A, Falcao-Pires I, Fontoura D, Leite S, Plettig L, Lopez B, Ottenheijm CA, Becher PM, et al. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail. 2013;6(6):1239\u201349.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"1208_CR19","doi-asserted-by":"publisher","first-page":"e006416","DOI":"10.1161\/JAHA.117.006416","volume":"6","author":"TS Bowen","year":"2017","unstructured":"Bowen TS, Brauer D, Rolim NPL, Baekkerud FH, Kricke A, Ormbostad Berre AM, Fischer T, Linke A, da Silva GJ, Wisloff U, et al. Exercise training reveals inflexibility of the diaphragm in an animal model of patients with obesity-driven heart failure with a preserved ejection fraction. J Am Heart Assoc. 2017;6(10):e006416.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1208_CR20","doi-asserted-by":"publisher","first-page":"e13378","DOI":"10.1111\/apha.13378","volume":"228","author":"D Miranda-Silva","year":"2020","unstructured":"Miranda-Silva D, Wust RCI, Conceicao G, Goncalves-Rodrigues P, Goncalves N, Goncalves A, Kuster DWD, Leite-Moreira AF, van der Velden J, de Sousa Beleza JM, et al. Disturbed cardiac mitochondrial and cytosolic calcium handling in a metabolic risk-related rat model of heart failure with preserved ejection fraction. Acta Physiol (Oxf). 2020;228(3):e13378.","journal-title":"Acta Physiol (Oxf)"},{"key":"1208_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.yjmcc.2017.12.012","volume":"115","author":"F Hohendanner","year":"2018","unstructured":"Hohendanner F, Bode D, Primessnig U, Guthof T, Doerr R, Jeuthe S, Reimers S, Zhang K, Bach D, Wakula P, et al. Cellular mechanisms of metabolic syndrome-related atrial decompensation in a rat model of HFpEF. J Mol Cell Cardiol. 2018;115:10\u20139.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"1208_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1124\/jpet.114.214304","volume":"350","author":"DR Powell","year":"2014","unstructured":"Powell DR, DaCosta CM, Smith M, Doree D, Harris A, Buhring L, Heydorn W, Nouraldeen A, Xiong W, Yalamanchili P, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther. 2014;350(2):232\u201342.","journal-title":"J Pharmacol Exp Ther"},{"key":"1208_CR23","first-page":"e57953","volume":"137","author":"D Bode","year":"2018","unstructured":"Bode D, Guthof T, Pieske BM, Heinzel FR, Hohendanner F. Isolation of atrial cardiomyocytes from a rat model of metabolic syndrome-related heart failure with preserved ejection fraction. J Vis Exp. 2018;137:e57953.","journal-title":"J Vis Exp"},{"issue":"2","key":"1208_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCULATIONAHA.113.006641","volume":"129","author":"N Voigt","year":"2014","unstructured":"Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XHT, Nattel S, Dobrev D. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129(2):145\u201356.","journal-title":"Circulation"},{"issue":"6","key":"1208_CR25","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1113\/jphysiol.2014.283226","volume":"593","author":"F Hohendanner","year":"2015","unstructured":"Hohendanner F, Walther S, Maxwell JT, Kettlewell S, Awad S, Smith GL, Lonchyna VA, Blatter LA. Inositol-1,4,5-trisphosphate induced Ca2+ release and excitation-contraction coupling in atrial myocytes from normal and failing hearts. J Physiol. 2015;593(6):1459\u201377.","journal-title":"J Physiol"},{"issue":"5","key":"1208_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCRESAHA.113.300895","volume":"113","author":"F Hohendanner","year":"2013","unstructured":"Hohendanner F, Ljubojevic S, MacQuaide N, Sacherer M, Sedej S, Biesmans L, Wakula P, Platzer D, Sokolow S, Herchuelz A, et al. Intracellular dyssynchrony of diastolic cytosolic [Ca(2)(+)] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure. Circ Res. 2013;113(5):527\u201338.","journal-title":"Circ Res"},{"key":"1208_CR27","first-page":"e57225","volume":"134","author":"JT Maxwell","year":"2018","unstructured":"Maxwell JT, Tsai CH, Mohiuddin TA, Kwong JQ. Analyses of mitochondrial calcium influx in isolated mitochondria and cultured cells. J Vis Exp JoVE. 2018;134:e57225.","journal-title":"J Vis Exp JoVE"},{"key":"1208_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa123","author":"D Kolijn","year":"2020","unstructured":"Kolijn D, Pabel S, Tian Y, Lodi M, Herwig M, Carrizzo A, Zhazykbayeva S, Kovacs A, Fulop GA, Falcao-Pires I, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Galpha oxidation. Cardiovasc Res. 2020. https:\/\/doi.org\/10.1093\/cvr\/cvaa123.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1208_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/19336950.2015.1040966","volume":"9","author":"F Hohendanner","year":"2015","unstructured":"Hohendanner F, Maxwell JT, Blatter LA. Cytosolic and nuclear calcium signaling in atrial myocytes: IP3-mediated calcium release and the role of mitochondria. Channels (Austin). 2015;9(3):129\u201338.","journal-title":"Channels (Austin)"},{"issue":"17","key":"1208_CR30","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1161\/CIRCULATIONAHA.111.067306","volume":"125","author":"N Voigt","year":"2012","unstructured":"Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland T, Ravens U, Nattel S, et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125(17):2059\u201370.","journal-title":"Circulation"},{"issue":"12","key":"1208_CR31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/ejhf.1619","volume":"21","author":"U Primessnig","year":"2019","unstructured":"Primessnig U, Bracic T, Levijoki J, Otsomaa L, Pollesello P, Falcke M, Pieske B, Heinzel FR. Long-term effects of Na(+) \/Ca(2+) exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction. Eur J Heart Fail. 2019;21(12):1543\u201352.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1208_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722\u20136.","journal-title":"Diabetologia"},{"issue":"2","key":"1208_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1161\/01.RES.0000232546.92777.05","volume":"99","author":"C Maack","year":"2006","unstructured":"Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, O\u2019Rourke B. Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res. 2006;99(2):172\u201382.","journal-title":"Circ Res"},{"issue":"32","key":"1208_CR34","doi-asserted-by":"publisher","first-page":"12986","DOI":"10.1073\/pnas.1210718109","volume":"109","author":"I Drago","year":"2012","unstructured":"Drago I, De Stefani D, Rizzuto R, Pozzan T. Mitochondrial Ca2+ uptake contributes to buffering cytoplasmic Ca2+ peaks in cardiomyocytes. Proc Natl Acad Sci USA. 2012;109(32):12986\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1208_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jacbts.2017.06.008","volume":"2","author":"MK Schweitzer","year":"2017","unstructured":"Schweitzer MK, Wilting F, Sedej S, Dreizehnter L, Dupper NJ, Tian Q, Moretti A, My I, Kwon O, Priori SG, et al. Suppression of arrhythmia by enhancing mitochondrial Ca(2+) uptake in catecholaminergic ventricular tachycardia models. JACC Basic Transl Sci. 2017;2(6):737\u201347.","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"1208_CR36","first-page":"1395","volume":"1787","author":"JJ Lemasters","year":"2009","unstructured":"Lemasters JJ, Theruvath TP, Zhong Z, Nieminen AL. Mitochondrial calcium and the permeability transition in cell death. Biochem Biophys Acta. 2009;1787(11):1395\u2013401.","journal-title":"Biochem Biophys Acta"},{"issue":"2","key":"1208_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/cvr\/cvq231","volume":"88","author":"DA Brown","year":"2010","unstructured":"Brown DA, O\u2019Rourke B. Cardiac mitochondria and arrhythmias. Cardiovasc Res. 2010;88(2):241\u20139.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"1208_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","volume":"64","author":"BR Lindman","year":"2014","unstructured":"Lindman BR, Davila-Roman VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1208_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019;18(1):20.","journal-title":"Cardiovasc Diabetol"},{"key":"1208_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejphar.2018.09.019","volume":"838","author":"V Tsimihodimos","year":"2018","unstructured":"Tsimihodimos V, Filippas-Ntekouan S, Elisaf M. SGLT1 inhibition: Pros and cons. Eur J Pharmacol. 2018;838:153\u20136.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1208_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-018-0741-9","volume":"17","author":"KA Connelly","year":"2018","unstructured":"Connelly KA, Zhang Y, Desjardins JF, Thai K, Gilbert RE. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc Diabetol. 2018;17(1):99.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1208_CR42","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cvr\/cvz037","volume":"115","author":"Z Li","year":"2019","unstructured":"Li Z, Agrawal V, Ramratnam M, Sharma RK, D\u2019Auria S, Sincoular A, Jakubiak M, Music ML, Kutschke WJ, Huang XN, et al. Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia\/reperfusion injury. Cardiovasc Res. 2019;115(11):1646\u201358.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1208_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12933-019-0889-y","volume":"18","author":"A Yoshii","year":"2019","unstructured":"Yoshii A, Nagoshi T, Kashiwagi Y, Kimura H, Tanaka Y, Oi Y, Ito K, Yoshino T, Tanaka TD, Yoshimura M. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Cardiovasc Diabetol. 2019;18(1):85.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1208_CR44","doi-asserted-by":"publisher","first-page":"E1039","DOI":"10.1152\/ajpendo.00507.2001","volume":"282","author":"HS Leong","year":"2002","unstructured":"Leong HS, Grist M, Parsons H, Wambolt RB, Lopaschuk GD, Brownsey R, Allard MF. Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact? Am J Physiol Endocrinol Metab. 2002;282(5):E1039-1045.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"1208_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00109-012-0982-0","volume":"91","author":"L Piao","year":"2013","unstructured":"Piao L, Sidhu VK, Fang YH, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD, et al. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl). 2013;91(3):333\u201346.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"1208_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10020-018-0005-x","volume":"24","author":"N Fillmore","year":"2018","unstructured":"Fillmore N, Levasseur JL, Fukushima A, Wagg CS, Wang W, Dyck JRB, Lopaschuk GD. Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction. Mol Med. 2018;24(1):3.","journal-title":"Mol Med"},{"issue":"12","key":"1208_CR47","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1113\/JP273609","volume":"595","author":"M Kohlhaas","year":"2017","unstructured":"Kohlhaas M, Nickel AG, Maack C. Mitochondrial energetics and calcium coupling in the heart. J Physiol. 2017;595(12):3753\u201363.","journal-title":"J Physiol"},{"issue":"1","key":"1208_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, Zhao J, Zhao Y, Li G, Liu T. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18(1):165.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-01208-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T20:11:22Z","timestamp":1610050282000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01208-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01208-z","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were approved by local authorities (G0317\/17 and G0276\/16).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and right to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lexicon Pharmaceuticals and Sanofi-Aventis provided sotagliflozin used for this study. D.P., employed by Lexicon Pharmaceuticals, as well as R.D. and H.R., employed by Sanofi-Aventis, have been involved in the development of sotagliflozin. The other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}